Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mixed results for a malaria vaccine

    Nature Medicine volume 17, pages 1560–1561 (2011)Cite this article

    Subjects

    Victor Nussenzweig

    This is a preview of subscription content, access via your institution

    Access options

    Rent or buy this article

    Prices vary by article type

    from$1.95

    to$39.95

    Learn more

    Prices may be subject to local taxes which are calculated during checkout

    References

    1. The RTS,S Cinical Trials Partnership. first results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. published online, 10.1056/nejmoa1102287 (18 October 2011).

    2. Cohen, J., Nussenzweig, V., Nussenzweig, R., Vekemans, J. & Leach, A. From the circumsporozoite protein to the RTS, S vaccine. Hum. Vaccin. 6, 90–96 (2010).

      Article  CAS  PubMed  Google Scholar 

    3. Stewart, V.A. et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75, 2283–2290 (2007).

      Article  CAS  PubMed  Google Scholar 

    4. Bojang, K.A. et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927–1934 (2001).

      Article  CAS  PubMed  Google Scholar 

    5. Good, M.F. Our impasse in developing a malaria vaccine. Cell. Mol. Life Sci. 68, 1105–1113 (2011).

      Article  CAS  PubMed  Google Scholar 

    6. Barry, A.E., Schultz, L., Buckee, C.O. & Reeder, J.C. et al. Contrasting population structures of the genes encoding ten leading malaria vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS One 4, e8497 (2009).

      Article  PubMed  Google Scholar 

    7. Bejon, P. et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359, 2521–2532 (2008).

      Article  CAS  PubMed  Google Scholar 

    8. Asante, K.P. et al. Safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect. Dis. 11, 741–749 (2011).

      Article  CAS  PubMed  Google Scholar 

    9. Moorthy, V., Reed, Z. & Smith, P.G. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 25, 5115–5123 (2007).

      Article  CAS  PubMed  Google Scholar 

    10. Alonso, P.L. et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012–2018 (2005).

      Article  CAS  PubMed  Google Scholar 

    Download references

    Ethics declarations

    Competing interests

    A.V.S.H. has collaborated with GlaxoSmithKline Biologicals in assessment of RTS,S vaccines and is a developer of other malaria vaccine candidates.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Mixed results for a malaria vaccine. Nat Med 17, 1560–1561 (2011). https://doi.org/10.1038/nm1211-1560

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1038/nm1211-1560

    This article is cited by

    Search

    Advanced search

    Quick links

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing